Sang-A Frontec (089980) Fundamentals 2026 — P/E 43.1x, Revenue Analysis | SniperIQ
Sang-A Frontec (089980) is a KR-listed Technology company in Hardware, Equipment & Parts with a market capitalization of ₩208.3B, trading at ₩13320.00 on the KOE. This SniperIQ fundamentals page covers Sang-A Frontec's valuation (P/E 43.1x, P/B 1.0x), profitability (net margin 2.4%), revenue (₩195.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Sang-A Frontec's market cap?
Sang-A Frontec (089980) has a market capitalization of approximately ₩208.3B, trading at ₩13320.00 on the KOE. Market cap moves with the live share price.
What is Sang-A Frontec's P/E ratio?
Sang-A Frontec's trailing twelve-month P/E ratio is 43.1x, with a price-to-book (P/B) of 1.0x. Valuation multiples are best compared with Technology sector peers rather than read in isolation.
How profitable is Sang-A Frontec?
Sang-A Frontec runs a net profit margin of 2.4%, a gross margin of 16.7%, and an operating margin of 3.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Sang-A Frontec generate?
Sang-A Frontec reported revenue of ₩195.6B for fiscal year 2025, with net income of ₩6.8B and earnings per share (EPS) of 433. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Sang-A Frontec pay a dividend?
Sang-A Frontec offers a trailing dividend yield of about 1.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Sang-A Frontec financially healthy?
Sang-A Frontec carries a debt-to-equity ratio of 0.68x and a current ratio of 0.97x, with a market beta of 1.09. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Sang-A Frontec a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Sang-A Frontec (089980) the key facts are: market cap ₩208.3B, P/E 43.1x, revenue ₩195.6B, 52-week range 12100-30050. Weigh valuation, profitability, growth, and balance-sheet strength against Technology peers and form your own view.
Track Sang-A Frontec's full fundamentals live
Get Sang-A Frontec's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.